Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| RNA vaccine | 42 | - | - | 0.50 [0.11; 2.28], 2 RCTs, I2=0%
inconclusive result | - | |
| Inactivated virus vaccine | 10 | - | - | OBS 0.20 [0.14; 0.28], 1 study, I2=0%
unassessable degree of certainty | - | |
| Non replicating viral vector | 10 | - | - | 0.19 [0.06; 0.64], 2 RCTs, I2=0%
moderate degree of certainty | - | |
| protein subunit vaccine | 3 | - | - | - | - | |
| vaccine 3rd dose | 2 | - | - | - | - | |
| heterologous prime-boost | 1 | - | - | - | - | |
| A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725) | 0 | - | - | - | - | |
| BBV152 (Bharat Biotech, India) | 0 | - | - | - | - | |
| BCG vaccination | 0 | - | - | - | - | |
| CureVac | 0 | - | - | - | - | |
| DNA vaccine | 0 | - | - | - | - | |
| Sanofi/GSK recombinant protein vaccine | 0 | - | - | - | - | |
| SCB-2019 | 0 | - | - | - | - | |
| sequential Immunization | 0 | - | - | - | - | |
| Shifa-Pharmed inactivated vaccine | 0 | - | - | - | - | |
| Vero cell | 0 | - | - | - | - | |
| virus-like particles vaccine | 0 | - | - | - | - | |
| Zy-Cov-D (Zydus Cadila) | 0 | - | - | - | - | |
